Sramana Mitra: What is the situation vis-a-vis startup biotech companies that want to use a platform like Atomwise? Is Atomwise seeing startup biotech companies build on their platform?
As you know, I categorically support bootstrapped entrepreneurs. There are numerous startups now that have achieved some revenue without any external funding. However, it has taken time. Sometimes, it has taken 5-7 years to get there. VCs, however, are looking for velocity. Their goal is to achieve $100M in 5-7 years.
Today’s 666th FREE online 1Mby1M Roundtable for Entrepreneurs is starting NOW, on Thursday, December 19, at 8 a.m. PST / 11 a.m. EST / 5 p.m. CET / 9:30 p.m. India IST. CLICK HERE to join. PASSWORD: startup All are welcome!
Today’s 666th FREE online 1Mby1M Roundtable for Entrepreneurs is starting in 30 minutes, on Thursday, December 19, at 8 a.m. PST / 11 a.m. EST / 5 p.m. CET / 9:30 p.m. India IST. CLICK HERE to join. PASSWORD: startup All are welcome!
I have been running 1Mby1M since 2010. Each year is a new beginning. Let’s start 2025 right!
Sramana Mitra: Could you talk a little bit about the financing journey of a company that has a 10-15 year lifecycle?
Sramana Mitra: So let’s double click down on drug discovery. It’s something that I’ve been spending time on as well. What have you invested in and how are you thinking about AI-enabled drug discovery? What’s the criteria of what you want to invest in and what have you invested in?
Mo Islam, Partner at Threshold Ventures. discusses his firm’s AI investment thesis. We had an excellent discussion on AI-enabled drug discovery, AI-enabled medical imaging, etc.